British-Swedish multinational pharmaceutical firm AstraZeneca has teamed up with Roche and Qiagen for developing two separate diagnostic tests using blood samples.
The new tests are very advanced as they are based on smart technology.
The test will help the doctors to spot the epidermal growth factor receptor (EGFR) mutations in tumor tissue and plasma of the patients with non-small-cell lung cancer (NSCLC).
The diagnostic test will also be used to optimize the clinical development of AZD9291, AstraZeneca’s investigational compound, for NSCLC.
The small fragments of circulating tumor DNA through the plasma of blood of the patients can be detected through the tests.
At present the doctors collect tissue samples through needle biopsy or surgery to know whether tumors contain genetic mutations, which make tumors suitable for drug treatment.
“We are committed for development of targeted medicines that can improve health outcomes for patients. Understanding the nature of tumors of each patient and therefore which medicine is most likely to benefit them is vital if we are to transform the way cancer patients are diagnosed and treated,” said Mondher Mahjoubi, senior vice president of Global Product Strategy for Oncology at AstraZeneca.
AstraZeneca in association with Qiagen will develop a test to accompany the former’s established lung cancer pill Iressa. However, the collaboration with Roche is for development of a companion diagnostic to go with AZD9291, the company’s experimental successor to Iressa.